Business Telegraph

.

PADCEV™ (enfortumab vedotin) treatment for Locally Advanced or Metastatic Urothelial Cancer receives market authorisation in Singapore

  • Written by Telegraph Magazine

Enfortumab vedotin is the first antibody drug conjugate approved in Singapore for la/mUC patients who received a prior platinum-containing chemotherapy and a PD-1/L1 inhibitor.

SINGAPORE - Media OutReach - 6 June 2022 - Astellas Pharma Inc.

Read more: PADCEV™ (enfortumab vedotin) treatment for Locally Advanced or Metastatic Urothelial Cancer...

More Articles ...

  1. Sunlight REIT secures an additional HK$800 million Sustainability-linked Loan from BOCHK
  2. Comba Telecom Releases 4G/5G (8TR) Green Integrated Base Station Antenna
  3. AWS and HKSTP Announce Strategic Collaboration to Accelerate Innovation and Technology Development in Hong Kong
  4. SUNeVision Welcomes the Court of Appeal's Ruling on Potential Breaches of Lease Conditions of Data Centers in HKSTP Industrial Estates
  5. Drunk Robots Finds New Partners and Increases the Prize Pool in $METAL
  6. Meta Health Appoints Dr Bernard Ng as Chairman of the Board and Group CEO
  7. Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory
  8. WEAVE LIVING and PGIM REAL ESTATE Join Forces for a USD200 Million Urban Living Joint Venture
  9. AXA launches "AXA Climate School for university students in Hong Kong"
  10. Hantec Financial will attend Wiki Finance Expo 2022 in Vietnam, HCMC